Abstract 1652: Preclinical characterization of ICT-011, a first-in-class, highly selective, potent and orally bioavailable MET degrader for the treatment of NSCLC harboring MET amplification
Authors: Jong Seok Kang, Yo Han Hong, Yong Hwan Kim, Hyeji Lee, Ji-Seong Yoon, Kyusic Jang, Bo Kyoung Kim, Young-Jun Shin, Moon Hwan Kim, Hye-Dong Yoo